1. A pharmaceutical composition comprising a combination of (rac) -tramadol HCl and celecoxib or a pharmaceutically acceptable salt or hydrate thereof. 2. The pharmaceutical composition of claim 1, wherein celecoxib is in neutral form. The pharmaceutical composition according to claim 1, wherein the ratio of (rac) -tramadol HCl to celecoxib is a molar ratio of from about 1: 1 to about 1: 300, or from about 1: 1 to about 300: 1.4. The pharmaceutical composition according to claim 1, wherein the molecular ratio of (rac) -tramadol HCl to celecoxib is a molar ratio of from about 1: 1 to about 1:30, or from about 1: 1 to about 30: 1.5. The pharmaceutical composition of claim 1, wherein the molecular ratio of (rac) -tramadol HCl to celecoxib is a molar ratio of from about 1: 1 to about 1: 5, or from about 1: 1 to about 5: 1.6. The pharmaceutical composition according to any one of claims 1 to 5 for use as an anesthetic or for the treatment of pain, preferably acute pain, chronic pain, neuropathic pain, nociceptive pain, mild pain, and from severe to moderate pain, hyperalgesia, pain associated with central sensitization, allodynia, or cancer pain, including diabetic neuropathy or diabetic peripheral neuropathy and osteoarthritis, fibromyalgia； rheumatoid arthritis, ankylosing spondylitis, shoulder-shoulder periarthritis or sciatica.1. Фармацевтическая композиция, включающая комбинацию (rac)-трамадола HCl и целекоксиба или его фармацевтически приемлемой соли или гидрата.2. Фармацевтическая композиция по п.1, где целекоксиб находится в нейтральной форме.3. Фармацевтическая композиция по п.1, где соотношение (rac)-трамадола HCl к целекоксибу представляет собой молярное соотношение от около 1:1 до около 1:300 или от около 1:1 до около 300:1.4. Фармацевтическая композиция по п.1, где молекулярное соотношение (rac)-трамадола HCl к целекоксибу представляет собой молярное соотношение от около 1:1 до около 1:30 или от около 1:1 до около 30:1.5. Фармацевтическая композиция по п.1,
